R3 Stem Cell lands CIO Bulletin recognition for 2026

R3 Stem Cell said it was named to CIO Bulletin’s Best Regenerative Medicine & Stem Cell Training Companies 2026 list, alongside a September cover profile on founder and CEO Dr. David Greene. The recognition spotlights the company’s global training and treatment footprint as it expands into new cell therapies.

Why it matters: - R3 Stem Cell’s latest recognition adds outside visibility to a business that says it is scaling regenerative medicine training and treatment across multiple countries. - The honor comes as the company pushes into new therapies, including Natural Killer cell immunotherapy, which could broaden its clinical pipeline if testing succeeds.

What happened: - R3 Stem Cell announced it was named to CIO Bulletin’s “Best Regenerative Medicine & Stem Cell Training Companies 2026” list. - CIO Bulletin also ran an extensive cover profile on founder and CEO Dr. David Greene in its September 2026 edition. - Greene discussed the company’s origins, clinical and research milestones, and plans for the future in that profile.

The details: - R3 Stem Cell operates more than 90 Centers of Excellence across eight countries. - The company says it has performed more than 30,000 stem cell and exosome procedures over the past decade. - R3 Stem Cell holds Institutional Review Board approval for a Global Observational Safety Database for umbilical cord stem cell therapies, which the company says is unique among U.S. organizations. - The company offers more than 20 customized treatment protocols and reports an 85% patient satisfaction rate. - R3 Stem Cell was founded in 2011 while Greene was completing his Executive MBA at Arizona State University. - The company says its portfolio includes stem cell and exosome protocols, a proprietary Regenerative Trifecta combination therapy, and physician training through R3 Medical Training. - R3 Medical Training uses live-patient instruction rather than cadavers or animal tissue, including MSK Ultrasound injection courses. - The company has published more than a dozen peer-reviewed research studies. - R3 Stem Cell says it has vertically integrated its supply chain through GMP tissue processing labs in Scottsdale, Arizona, and Pakistan. - The company says public figures who have shared treatment experiences include Dennis Quaid, Arnel Pineda, Butterbean, Shannon Briggs, Titus O’Neill, and Vernon Davis. - R3’s YouTube channel has grown to more than 1,500 educational videos. - R3 Stem Cell says it offers free consultations globally by calling +1 (844) GET-STEM.

Between the lines: - The company is using awards, media exposure, patient stories, and training programs to reinforce its position in a crowded regenerative medicine market. - Greene’s comments point to a strategy that combines broader consumer access, lower price points, and international expansion. - The planned NK cell work suggests R3 Stem Cell wants to move beyond standard regenerative offerings into adjacent cell-based immunotherapy.

What’s next: - R3 Stem Cell is developing Natural Killer cell immunotherapy with a university research team. - Testing is underway to evaluate the therapy against multiple cancer cell lines and its potential role in treating autoimmune conditions. - Greene said he wants to keep expanding the business into more countries while growing R3 Stem Cell into what he described as “the Marriott of stem cell therapy.”

The bottom line: - R3 Stem Cell is pairing media recognition with a broader push into training, research and new cell therapies as it tries to deepen its global footprint.